Cenix BioScience follows up successful RNAi-based target discovery screens with target validation study for AstraZeneca

(PresseBox) ( Dresden, Germany, )
Cenix BioScience GmbH, a leading RNA interference (RNAi)-focused contract research organization, today announced that it has initiated a second research project under its existing framework research agreement with AstraZeneca Pharmaceuticals LP, one of the world's leading pharmaceutical companies.

The new project will focus on detailed cell-based studies to further advance the validation of novel oncology target candidates successfully identified by Cenix in screens completed recently for AstraZeneca. Both the original screens and the new validation work are driven by the core Cenix expertise in combining high throughput RNAi-based gene silencing with high content phenotypic analyses. Cenix will adapt and implement multi-parametric microscopybased analyses of RNAi-induced loss-of-function phenotypes using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and therapeutic development potential of tested genes.

"We view the success of these first quite ambitious screens now completed for our colleagues at AstraZeneca as a clear testament to the strong scientific, technical and strategic synergies jointly achieved between our two teams," said Dr. Christophe Echeverri, CEO/CSO of Cenix. "We welcome the chance to continue assisting AstraZeneca in the crucially important process of target validation to further advance their oncology pipeline."

Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.